Protocol Ledger

NCT06369285 · Phase II · RECRUITING

A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

Interventional Phase II clinical trial protocol NCT06369285 sponsored by Puma Biotechnology in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-11-19 Enrollment: 225 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06369285
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)225 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06369285
Protocol FieldVerified Registry Value
NCT IdentifierNCT06369285
Consolidated Lead SponsorPuma Biotechnology
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment225 participants (ESTIMATED)
Registered Start Date2024-11-19
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06369285
Hospital Research SiteLocationSite Profile
Mayo Clinic ArizonaPhoenix, AZOpen Hospital Dossier ->
Beverly Hills Cancer CenterBeverly Hills, CAOpen Hospital Dossier ->
City of Hope Orange CountyIrvine, CAOpen Hospital Dossier ->
UCLA Health and Jonsson Comprehensive Cancer CenterLos Angeles, CAOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI